Form 4: Gilead Sciences Director, Jacqueline K. Barton, Reports Stock Option Grant and RSU Acquisition

Director Jacqueline K. Barton reports acquisition of restricted stock units and stock options in Gilead Sciences, Inc.

Summary

• Jacqueline K. Barton, a director of Gilead Sciences, Inc., filed a Form 4 disclosing changes in her beneficial ownership.
• On May 7, 2025, Barton acquired 1,516 restricted stock units (RSUs) under the 2022 Equity Incentive Plan, which vested immediately.
• Each RSU represents the right to receive one share of Gilead Sciences, Inc.'s common stock.
• Additionally, Barton acquired a non-qualified stock option to buy 6,809 shares of common stock at an exercise price of $98.90, which also vested immediately.
• Following these transactions, Barton directly owns 26,056 shares of common stock and 6,809 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of equity grants, neither particularly positive nor negative.

Positives

• The immediate vesting of both the RSUs and stock options suggests confidence in the director's continued service and the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the grant of equity suggests an expectation of continued service and alignment with shareholder interests.

Industry Context

This filing is a routine disclosure of insider transactions, common in publicly traded companies. It provides transparency into the compensation and equity ownership of company directors.

Comparison to Industry Standards

• Equity grants, including RSUs and stock options, are a common form of compensation for directors in publicly traded companies, particularly in the biotechnology and pharmaceutical industries.
• Companies like Amgen (AMGN) and Johnson & Johnson (JNJ) also utilize similar equity-based compensation plans for their directors to align their interests with those of shareholders.

Stakeholder Impact

• The equity grants align the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

Keywords

Form 4, Gilead Sciences, Director, RSU, Stock Option, Beneficial Ownership, GILD